pSivida Corp Reports First Orders For ILUVIEN® Shipped For U.K. National Health Service Hospitals Less Than Seven Weeks After Final National Institute for Clinical Excellence (NICE) Guidance
Published: Jan 13, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN® to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
Help employers find you! Check out all the jobs and post your resume.